S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
10 e-commerce stocks to consider for long-term buys
Ex-banker’s #1 trading tip (Ad)
3 reasons to buy AMD before 2024
How does the Consumer Price Index affect the stock market?
Massive new discovery... (Ad)
3 biotech powerhouses poised to thrive amid sector rebound
Broadcom falls into a buy-the-dip opportunity 
Massive new discovery... (Ad)
Closing prices for crude oil, gold and other commodities
Carrier Global, Marathon Oil rise; RH, Newmont fall, Friday, 12/8/2023
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
10 e-commerce stocks to consider for long-term buys
Ex-banker’s #1 trading tip (Ad)
3 reasons to buy AMD before 2024
How does the Consumer Price Index affect the stock market?
Massive new discovery... (Ad)
3 biotech powerhouses poised to thrive amid sector rebound
Broadcom falls into a buy-the-dip opportunity 
Massive new discovery... (Ad)
Closing prices for crude oil, gold and other commodities
Carrier Global, Marathon Oil rise; RH, Newmont fall, Friday, 12/8/2023
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
10 e-commerce stocks to consider for long-term buys
Ex-banker’s #1 trading tip (Ad)
3 reasons to buy AMD before 2024
How does the Consumer Price Index affect the stock market?
Massive new discovery... (Ad)
3 biotech powerhouses poised to thrive amid sector rebound
Broadcom falls into a buy-the-dip opportunity 
Massive new discovery... (Ad)
Closing prices for crude oil, gold and other commodities
Carrier Global, Marathon Oil rise; RH, Newmont fall, Friday, 12/8/2023
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
10 e-commerce stocks to consider for long-term buys
Ex-banker’s #1 trading tip (Ad)
3 reasons to buy AMD before 2024
How does the Consumer Price Index affect the stock market?
Massive new discovery... (Ad)
3 biotech powerhouses poised to thrive amid sector rebound
Broadcom falls into a buy-the-dip opportunity 
Massive new discovery... (Ad)
Closing prices for crude oil, gold and other commodities
Carrier Global, Marathon Oil rise; RH, Newmont fall, Friday, 12/8/2023

Adverum Biotechnologies (ADVM) News Today

$0.90
-0.11 (-10.89%)
(As of 12/8/2023 ET)
Compare
Today's Range
$0.88
$1.04
50-Day Range
$0.81
$1.26
52-Week Range
$0.53
$2.34
Volume
408,462 shs
Average Volume
382,507 shs
Market Capitalization
$90.93 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.50
SourceHeadline
finance.yahoo.com logoAdverum Biotechnologies to Present LUNA Preliminary Efficacy and Safety Data at the 47th Annual Meeting of the Macula Society
finance.yahoo.com - December 7 at 7:57 PM
MarketBeat logoAdverum Biotechnologies, Inc. (NASDAQ:ADVM) Short Interest Update
americanbankingnews.com - December 2 at 1:26 AM
markets.businessinsider.com logoPromising Developments in Adverum Biotechnologies’ Gene Therapy Candidate, Ixo-Vec, Drive Graig Suvannavejh’s Bullish Rating
markets.businessinsider.com - November 21 at 8:15 AM
markets.businessinsider.com logoRBC Capital Reaffirms Their Hold Rating on Adverum Biotechnologies (ADVM)
markets.businessinsider.com - November 11 at 1:21 PM
finance.yahoo.com logoAdverum Biotechnologies Reports Third Quarter 2023 Financial Results and Pipeline Highlights
finance.yahoo.com - November 9 at 5:33 PM
msn.com logoWhy Is Eye Disease-Focused Adverum Bio Stock Trading Higher Today?
msn.com - November 6 at 3:57 PM
finance.yahoo.com logoAdverum Biotechnologies Appoints C. David Nicholson, Ph.D. to its Board of Directors
finance.yahoo.com - November 6 at 9:40 AM
investing.com logoMizuho backs Adverum Biotechnologies despite revenue decrease forecast
investing.com - November 5 at 10:11 PM
benzinga.com logoAdverum Biotechnologies Announces 3-Year Efficacy and Safety Results from the OPTIC Extension Study in Patients with Wet AMD at AAO 2023
benzinga.com - November 4 at 8:03 PM
finance.yahoo.com logoAdverum Biotechnologies Announces 3-Year Efficacy and Safety Results from the OPTIC Extension Study in Patients with Wet AMD at AAO 2023
finance.yahoo.com - November 4 at 8:03 PM
msn.com logoMizuho Initiates Coverage of Adverum Biotechnologies (ADVM) with Buy Recommendation
msn.com - November 3 at 8:40 AM
finance.yahoo.com logo10 Biotech Stocks Below Cash Value with Key Catalysts on the Horizon: An Analysis
finance.yahoo.com - October 24 at 1:09 PM
finance.yahoo.com logoAdverum Biotechnologies to Participate in Upcoming Investor Conferences
finance.yahoo.com - September 21 at 6:08 PM
msn.com logoTruist Securities Reiterates Adverum Biotechnologies (ADVM) Buy Recommendation
msn.com - September 6 at 6:59 PM
finance.yahoo.com logoAdverum Biotechnologies to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
finance.yahoo.com - September 5 at 4:20 PM
msn.com logoAdverum Biotechnologies (ADVM) Price Target Increased by 13.33% to 4.34
msn.com - August 31 at 8:16 AM
finanznachrichten.de logoAdverum Biotechnologies, Inc.: Adverum Biotechnologies Appoints Andrew Ramelmeier, Ph.D. as Chief Technology Officer
finanznachrichten.de - August 22 at 7:31 AM
finance.yahoo.com logoAdverum Biotechnologies Appoints Andrew Ramelmeier, Ph.D. as Chief Technology Officer
finance.yahoo.com - August 21 at 4:30 PM
marketbeat.com logoAdverum Biotechnologies (NASDAQ:ADVM) Now Covered by Analysts at StockNews.com
marketbeat.com - August 17 at 2:43 AM
finance.yahoo.com logoAdverum Biotechnologies to Participate in the H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference
finance.yahoo.com - August 14 at 9:28 AM
msn.com logoChardan Capital Upgrades Adverum Biotechnologies (ADVM)
msn.com - August 12 at 3:52 PM
msn.com logoAdverum upgraded at Chardan ahead of key readouts for lead asset
msn.com - August 11 at 7:50 PM
marketbeat.com logoAdverum Biotechnologies (NASDAQ:ADVM) Rating Increased to Buy at Chardan Capital
marketbeat.com - August 11 at 8:00 AM
msn.com logoAdverum Biotechnologies (ADVM) Price Target Increased by 7.14% to 3.83
msn.com - August 2 at 7:48 AM
benzinga.com logoShort Volatility Alert: Adverum Biotechnologies
benzinga.com - June 22 at 1:53 PM
finance.yahoo.com logoAdverum Biotechnologies Grants License to Ray Therapeutics Inc. for the AAV.7m8 Intravitreal Capsid
finance.yahoo.com - June 12 at 4:15 PM
marketbeat.com logoGSA Capital Partners LLP Acquires 751,753 Shares of Adverum Biotechnologies, Inc. (NASDAQ:ADVM)
marketbeat.com - June 7 at 7:27 AM
finance.yahoo.com logoAdverum Biotechnologies to Participate in the Jefferies Healthcare Conference
finance.yahoo.com - June 2 at 8:47 AM
finance.yahoo.com logoAdverum Biotechnologies Announces New Executive Leadership Roles
finance.yahoo.com - May 25 at 11:09 AM
technews.tmcnet.com logoAdverum Biotechnologies Presents Nonclinical Data in Support of Ixo-vec's Phase 2 Clinical Development at ASGCT 2023 Annual Meeting
technews.tmcnet.com - May 18 at 2:22 PM
finance.yahoo.com logoAdverum Biotechnologies Introduces an Intravitreal Gene Therapy Program for Geographic Atrophy and Presents Data on Its Ocular Gene Therapy Platform
finance.yahoo.com - May 18 at 9:18 AM
finance.yahoo.com logoAdverum Biotechnologies Presents Nonclinical Data in Support of Ixo-vec’s Phase 2 Clinical Development at ASGCT 2023 Annual Meeting
finance.yahoo.com - May 18 at 9:18 AM
markets.businessinsider.com logoAdverum Biotechnologies (ADVM) Receives a Hold from RBC Capital
markets.businessinsider.com - May 16 at 1:50 AM
finance.yahoo.com logoAdverum Biotechnologies Reports First Quarter 2023 Financial Results
finance.yahoo.com - May 11 at 7:14 PM
finance.yahoo.com logoAdverum Biotechnologies to Participate in RBC Capital Markets Global Healthcare Conference
finance.yahoo.com - May 10 at 7:31 PM
tmcnet.com logoAdverum Biotechnologies Announces Upcoming Data Presentations at ASGCT
tmcnet.com - May 2 at 8:31 PM
finance.yahoo.com logoAdverum Biotechnologies Announces Upcoming Data Presentations at ASGCT 2023 including Data on a New Intravitreal (IVT) Geographic Atrophy Secondary to Dry AMD
finance.yahoo.com - May 2 at 8:31 PM
finance.yahoo.com logoAdverum Biotechnologies Presents Nonclinical Data at the 2023 ARVO Annual Meeting Supporting Potential for Staggered Bilateral Administration of Ixo-vec
finance.yahoo.com - April 23 at 2:40 PM
finance.yahoo.com logoAfter losing 12% in the past year, Adverum Biotechnologies, Inc. (NASDAQ:ADVM) institutional owners must be relieved by the recent gain
finance.yahoo.com - April 21 at 7:55 AM
finance.yahoo.com logoAdverum Biotechnologies Granted Innovative Licensing and Access Pathway Designation in the United Kingdom for Ixo-vec for the Treatment of Wet AMD
finance.yahoo.com - April 18 at 8:47 AM
finance.yahoo.com logoAdverum Biotechnologies Announces Upcoming Nonclinical Data Presentation Supporting Staggered Bilateral Administration of Ixoberogene Soroparvovec (Ixo-vec) at the 2023 ARVO Annual Meeting
finance.yahoo.com - April 17 at 4:11 PM
msn.com logoAdverum Biotechnologies GAAP EPS of -$0.33 beats by $0.03
msn.com - March 31 at 11:00 AM
finance.yahoo.com logoAdverum Biotechnologies Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Phase 2 LUNA Trial Update
finance.yahoo.com - March 30 at 6:26 PM
investing.com logoAdverum Biotechn (ADVM) Earnings Dates & Reports
investing.com - March 21 at 10:44 PM
msn.com logoLadenburg Thalmann Initiates Coverage of Adverum Biotechnologies (ADVM) with Buy Recommendation
msn.com - March 7 at 4:23 PM
nasdaq.com logoAdaptive Biotechnologies (ADPT) Shares Cross Above 200 DMA
nasdaq.com - January 12 at 7:52 AM
finance.yahoo.com logoGI CELL Enters Agreement with Optieum Biotechnologies
finance.yahoo.com - January 7 at 8:58 PM
finanznachrichten.de logoAdverum Biotechnologies, Inc.: Adverum Biotechnologies Reports Third Quarter 2022 Financial Results
finanznachrichten.de - November 12 at 7:52 AM
finance.yahoo.com logoAdverum Biotechnologies Reports Third Quarter 2022 Financial Results
finance.yahoo.com - November 10 at 4:19 PM
finance.yahoo.com logoAdverum Biotechnologies Presents Positive End of Study Results from the OPTIC Trial in Wet AMD Including Two-Year Outcomes Following a Single Intravitreal Injection of Ixo-vec (ADVM-022)
finance.yahoo.com - November 4 at 7:12 PM
Get Adverum Biotechnologies News Delivered to You Automatically

Sign up to receive the latest news and ratings for ADVM and its competitors with MarketBeat's FREE daily newsletter.



ADVM Media Mentions By Week

ADVM Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

ADVM
News Sentiment

1.42

0.52

Average
Medical
News Sentiment

ADVM News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

ADVM Articles
This Week

2

0

ADVM Articles
Average Week

Get Adverum Biotechnologies News Delivered to You Automatically

Sign up to receive the latest news and ratings for ADVM and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

This page (NASDAQ:ADVM) was last updated on 12/9/2023 by MarketBeat.com Staff

My Account -